Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, and is known to be associated with a poor prognosis and limited therapeutic options. Poly (ADP-ribose) polymerase inhibitors (PARPi) are targeted therapeutics that have demonstrated efficacy as monotherapy in metas...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Mariya Yordanova, Audrey Hubert, Saima Hassan
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	MDPI AG 2021-12-01
Schriftenreihe:	Pharmaceuticals
Schlagworte:	triple-negative breast cancer PARP inhibitors combination therapy predictive biomarkers
Online-Zugang:	https://www.mdpi.com/1424-8247/14/12/1270
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!